OGT signs license with Wellcome Trust Sanger Institute

Wednesday 1 April 2015
Product types:
Applications:
Sanger-logo_large

Oxford Gene Technology (OGT), the molecular genetics company, today announced that it has signed a license agreement with the Wellcome Trust Sanger Institute for access to data from the Deciphering Developmental Disorders (DDD) study.

The DDD study has successfully identified new areas of the genome as responsible for developmental disorders1, 2. OGT plans to use this ground-breaking information, combined with the latest updates from the International Collaboration for Clinical Genomics (ICCG) consortium, to develop its CytoSure Constitutional v3 range, an advance on OGT’s successful CytoSure ISCA arrays. The range will utilise both single nucleotide polymorphism (SNP) and copy number variation (CNV) probes for accurate identification of a broader range of genetic syndromes, detecting amplifications and deletions as well as regions of loss of heterozygosity (LOH).

The new range of arrays will incorporate OGT’s class-leading CytoSure Interpret Software, a powerful, easy-to-use package for the analysis of CNV and SNP data. OGT also offers the facility to transfer legacy data generated using other platforms, allowing more insightful analyses.

The DDD study is a collaboration between the UK's National Health Service (NHS), the Wellcome Trust and the Wellcome Trust Sanger Institute to conduct genome wide screening of over 12,000 individuals with developmental disorders to uncover the underlying genetic aberrations. New technologies such as high-resolution microarrays and exome sequencing were used by the study to identify previously undetected genetic changes in the samples. These newly identified genomic regions are included in OGT’s advanced array design, enabling more powerful analysis.

James Clough, Executive Vice President Commercial at OGT commented, “Working with the renowned Wellcome Trust Sanger Institute and the ICCG consortium will boost the evolution of our microarray and NGS products. Access to such extensive information and systematically carried out research into developmental disorders will provide OGT with the ability to offer the most advanced array designs available for accurately identifying developmental disorders”.

Dr Matthew Hurles, a scientific leader of the DDD study at the Wellcome Trust Sanger Institute commented, “The huge breadth of genetic information that this study has uncovered is vital in advancing the identification of developmental disorders. Through better detection, we can hope to further our understanding and support of these disorders.”

For more information about CytoSure Constitutional v3 arrays, please contact products@ogt.com

References

  1. Large-scale discovery of novel genetic causes of developmental disorders. The Deciphering Developmental Disorders Study. Nature 2014 PUBMED: 25533962; DOI: 10.1038/nature14135
  2. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, King DA,Ambridge K, Barrett DM, Bayzetinova T, Bevan AP, Bragin E, Chatzimichali EA, Gribble S,Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, Prigmore E, Rajan D,Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, Carter NP, Barrett JC, Hurles ME, FitzPatrick DR, Firth HV and on behalf of the DDD study. Lancet 2014

Notes for Editors:

About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.

For more information on the Company, please visit our website at www.ogt.com.

CytoSure™, SureSeq™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell: Some products may not be available in the US.

About Wellcome Trust Sanger Institute

The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.

www.sanger.ac.uk

For more information, please contact:

Oxford Gene Technology

Stephen Archibald, Director of Communications
T: +44 (0) 1865 856826
F: +44 (0) 1865 848684
E: contact@ogt.com
W: www.ogt.com

Instinctif Partners (PR Agency for OGT)

Daniel Gooch / Alex Bannister
T: +44 (0) 20 7866 7905
E: OGT@instinctif.com